Published in Cancer Epidemiol Biomarkers Prev on April 01, 2004
Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA. Clin Cancer Res (2008) 1.23
Screening behavior in women at increased familial risk for breast cancer. Fam Cancer (2006) 0.97
Factors associated with return for routine annual screening in an ovarian cancer screening program. Gynecol Oncol (2006) 0.84
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med (2007) 10.28
The case for early detection. Nat Rev Cancer (2003) 6.96
Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst (2002) 6.28
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer (2007) 4.76
Computational Proteomics Analysis System (CPAS): an extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments. J Proteome Res (2006) 4.32
The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res (2003) 4.13
Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J Proteome Res (2007) 3.48
Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst (2009) 3.48
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
Nine-year prospective relationship between parental smoking cessation and children's daily smoking. Addiction (2003) 3.14
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res (2008) 3.05
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) (2011) 3.03
A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat Biotechnol (2011) 2.91
Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med (2010) 2.58
Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One (2009) 2.37
Concordance of breast imaging reporting and data system assessments and management recommendations in screening mammography. Radiology (2002) 2.36
A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med (2008) 2.31
Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res (2009) 2.20
Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst (2005) 2.08
Head-to-head comparison of serum fractionation techniques. J Proteome Res (2007) 1.98
Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS One (2008) 1.93
Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol (2009) 1.84
Quality of life in long term survivors of colorectal cancer. Am J Gastroenterol (2002) 1.84
Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol (2009) 1.77
Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS One (2008) 1.72
Generating longitudinal screening algorithms using novel biomarkers for disease. Cancer Epidemiol Biomarkers Prev (2002) 1.57
Risk of upgrade of atypical ductal hyperplasia after stereotactic breast biopsy: effects of number of foci and complete removal of calcifications. Radiology (2010) 1.55
Frequency and upgrade rates of atypical ductal hyperplasia diagnosed at stereotactic vacuum-assisted breast biopsy: 9-versus 11-gauge. AJR Am J Roentgenol (2009) 1.55
Biomedical informatics for proteomics. Nature (2003) 1.54
Use of the American College of Radiology BI-RADS to report on the mammographic evaluation of women with signs and symptoms of breast disease. Radiology (2002) 1.53
Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer (2008) 1.53
Bead-based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res (2006) 1.52
Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.52
Complementary and alternative medicine provider use and expenditures by cancer treatment phase. Am J Manag Care (2008) 1.51
Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One (2011) 1.50
Breast MR imaging: computer-aided evaluation program for discriminating benign from malignant lesions. Radiology (2007) 1.50
A quantitative assay for telomere protection in Saccharomyces cerevisiae. Genetics (2002) 1.49
Prospective prediction of children's smoking transitions: role of parents' and older siblings' smoking. Addiction (2006) 1.49
Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule. J Clin Oncol (2012) 1.48
Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol Oncol (2007) 1.46
Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment. Cancer Lett (2007) 1.46
Early detection of ovarian cancer: promise and reality. Cancer Treat Res (2002) 1.45
A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker. Biostatistics (2003) 1.44
Potential role of HE4 in multimodal screening for epithelial ovarian cancer. J Natl Cancer Inst (2011) 1.39
Translational crossroads for biomarkers. Clin Cancer Res (2005) 1.38
Mammography surveillance following breast cancer. Breast Cancer Res Treat (2003) 1.33
BI-RADS lesion characteristics predict likelihood of malignancy in breast MRI for masses but not for nonmasslike enhancement. AJR Am J Roentgenol (2009) 1.33
Nine-year prediction of adolescent smoking by number of smoking parents. Addict Behav (2005) 1.32
Method for generation of in vivo biotinylated recombinant antibodies by yeast mating. J Immunol Methods (2006) 1.32
Use of the American College of Radiology BI-RADS guidelines by community radiologists: concordance of assessments and recommendations assigned to screening mammograms. AJR Am J Roentgenol (2002) 1.32
Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol (2006) 1.31
Effects of blood collection conditions on ovarian cancer serum markers. PLoS One (2007) 1.27
A new automated software system to evaluate breast MR examinations: improved specificity without decreased sensitivity. AJR Am J Roentgenol (2006) 1.26
Modification of host lipid raft proteome upon hepatitis C virus replication. Mol Cell Proteomics (2006) 1.26
Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery. Cancer Lett (2006) 1.25
Background parenchymal enhancement on breast MRI: impact on diagnostic performance. AJR Am J Roentgenol (2012) 1.25
Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling. J Proteome Res (2011) 1.25
Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. Cancer Res (2009) 1.24
Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA. Clin Cancer Res (2008) 1.23
Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells. J Proteome Res (2008) 1.22
Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q. Int J Cancer (2003) 1.22
Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol (2006) 1.20
Ovarian cancer screening. Hematol Oncol Clin North Am (2003) 1.20
Analysis of the cost-effectiveness of mammography promotion by volunteers in rural communities. Health Educ Behav (2002) 1.19
Childhood friends who smoke: do they influence adolescents to make smoking transitions? Addict Behav (2005) 1.18
Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. PLoS One (2009) 1.17
Early diagnosis of ovarian carcinoma: is a solution in sight? Radiology (2011) 1.16
Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol Biomarkers Prev (2009) 1.16
Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy. Acad Radiol (2004) 1.14
Diffusion tensor MRI: preliminary anisotropy measures and mapping of breast tumors. J Magn Reson Imaging (2010) 1.12
Clinical experience with MRI-guided vacuum-assisted breast biopsy. AJR Am J Roentgenol (2005) 1.11
The relationship between perceived risk, affect, and health behaviors. Cancer Detect Prev (2004) 1.11
CA125 in ovarian cancer. Biomark Med (2007) 1.10
Ovarian cancer early detection claims are biased. Clin Cancer Res (2008) 1.10
Changes in the influence of parents' and close friends' smoking on adolescent smoking transitions. Addict Behav (2006) 1.10
Parents' and older siblings' smoking during childhood: changing influences on smoking acquisition and escalation over the course of adolescence. Nicotine Tob Res (2007) 1.10
Characteristics of probably benign breast MRI lesions. AJR Am J Roentgenol (2009) 1.09
Effectiveness of telephone counseling for mammography: results from five randomized trials. Prev Med (2002) 1.08
Quantitative proteomics investigation of pancreatic intraepithelial neoplasia. Electrophoresis (2009) 1.08
Examining the cost-effectiveness of cancer screening promotion. Cancer (2004) 1.07
Quality control metrics for LC-MS feature detection tools demonstrated on Saccharomyces cerevisiae proteomic profiles. J Proteome Res (2006) 1.07
Breast cancer risk counseling improves women's functioning. Patient Educ Couns (2004) 1.06
Utility of targeted sonography for breast lesions that were suspicious on MRI. AJR Am J Roentgenol (2009) 1.05
Changes in cancer worry associated with participation in ovarian cancer screening. Psychooncology (2007) 1.04
BI-RADS MRI enhancement characteristics of ductal carcinoma in situ. Breast J (2007) 1.03
MRI-detected suspicious breast lesions: predictive values of kinetic features measured by computer-aided evaluation. AJR Am J Roentgenol (2009) 1.03
Use of high density antibody arrays to validate and discover cancer serum biomarkers. Mol Oncol (2007) 1.02